BioVersys raised €18M in a Series B round in Sep 2020. The company is based in Basel, Switzerland. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
